• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Pharma delivers another strong quarter for Johnson & Johnson

Pharma delivers another strong quarter for Johnson & Johnson

October 15, 2013 By Brad Perriello

Pharma delivers another strong quarter for Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) shares rose today after the healthcare conglomerate reported Wall-Street-beating 3rd-quarter results, buoyed by its pharmaceuticals division.

New Brunswick, N.J.-based J&J posted profits of $3.0 billion, or $1.04 per share, on sales of $17.58 billion for the 3 months ended Sept. 30, for bottom-line growth of 13.4% on sales growth of 3.1% compared with Q3 2012.

Adjusted to exclude 1-time items, earnings per share reached $1.36, beating expectations on The Street by 4¢. That, and a boost for JNJ’s full-year earnings outlook, boosted share prices today to $90.37 apiece as of about 11:30 a.m., up 0.6%.

"Our 3rd-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer term strategic growth drivers," chairman & CEO Alex Gorsky said in prepared remarks. "Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations. Our investments further strengthen our ability to deliver sustainable growth and bring meaningful innovations to patients and consumers."

Johnson & Johnson raised its adjusted earnings forecast for 2013 to $5.44-$5.49 per share, up from $5.40-$5.47. Analysts on The Street are looking for full-year adjusted EPS of $5.46.

Sales for the company’s medical device and diagnostics segment slipped 2% during the quarter to $6.93 billion, with U.S. sales down 4.2% to $3.15 billion and international sales down 0.1% to $3.78 billion. Leerink Swann analyst Danielle Antalffy said the below-consensus results for the device segment belies an uptick for J&J’s specialty surgical division. Sales for that business rose 4.9% to $626.0 million during the quarter.

"Overall, JNJ continues to ride the back of strong Pharma performance as recent product launches continue to exceed expectations," Antalffy wrote this morning in a note to investors. "And while below-consensus MD&D sales could perpetuate concerns that broader MedTech utilization trends remain weak, strong Surgical sales could actually signal potentially positive volume trends overall. While JNJ suffers several ‘weak’ spots – primarily in MD&D – the company should continue to benefit from positive tailwinds within Pharma and the ongoing Consumer turnaround, pushing shares higher still."

Filed Under: MassDevice Earnings Roundup, News Well, Pharmaceutical, Wall Street Beat Tagged With: 2013, Johnson and Johnson, Q3

More recent news

  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke
  • Carlsmed launches IPO roadshow
  • Varian introduces IntelliBlate for image-guided cancer therapy in Europe
  • Henry Schein CEO Stanley M. Bergman to retire

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy